JP2025506488A5 - - Google Patents
Info
- Publication number
- JP2025506488A5 JP2025506488A5 JP2024547510A JP2024547510A JP2025506488A5 JP 2025506488 A5 JP2025506488 A5 JP 2025506488A5 JP 2024547510 A JP2024547510 A JP 2024547510A JP 2024547510 A JP2024547510 A JP 2024547510A JP 2025506488 A5 JP2025506488 A5 JP 2025506488A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- sequence identity
- identity
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2201674.5 | 2022-02-09 | ||
| GB202201674 | 2022-02-09 | ||
| GBGB2209454.4A GB202209454D0 (en) | 2022-06-28 | 2022-06-28 | Therapeutic antibodies |
| GB2209454.4 | 2022-06-28 | ||
| PCT/GB2023/050281 WO2023152486A1 (en) | 2022-02-09 | 2023-02-08 | Therapeutic antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025506488A JP2025506488A (ja) | 2025-03-11 |
| JP2025506488A5 true JP2025506488A5 (enExample) | 2026-01-30 |
Family
ID=85283675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024547510A Pending JP2025506488A (ja) | 2022-02-09 | 2023-02-08 | 治療抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250340659A1 (enExample) |
| EP (1) | EP4476256A1 (enExample) |
| JP (1) | JP2025506488A (enExample) |
| KR (1) | KR20240139085A (enExample) |
| AU (1) | AU2023219227A1 (enExample) |
| CA (1) | CA3258958A1 (enExample) |
| CL (1) | CL2024002361A1 (enExample) |
| CO (1) | CO2024010901A2 (enExample) |
| IL (1) | IL314314A (enExample) |
| MX (1) | MX2024009898A (enExample) |
| WO (1) | WO2023152486A1 (enExample) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| AU2005229009A1 (en) * | 2004-03-23 | 2005-10-13 | Amgen, Inc. | Monoclonal antibodies specific for human OX40L (CD 134L) |
| US7812133B2 (en) * | 2005-12-16 | 2010-10-12 | Genentech, Inc | Anti-OX40L antibodies and methods using same |
| GB0525662D0 (en) | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Immunoglobulins |
| HRP20180858T1 (hr) | 2011-07-11 | 2018-09-21 | Glenmark Pharmaceuticals S.A. | Protutijela koja se vežu na ox40 i njihove uporabe |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| AU2013221502C1 (en) * | 2012-02-14 | 2018-03-01 | Boehringer Ingelheim Animal Health USA Inc. | Recombinant poxviral vectors expressing both rabies and OX40 proteins, and vaccines made therefrom |
| GB201316644D0 (en) | 2013-09-19 | 2013-11-06 | Kymab Ltd | Expression vector production & High-Throughput cell screening |
| US10196435B2 (en) | 2013-11-18 | 2019-02-05 | University Of Southern California | OX40L fusion protein for the immunotherapy of tumors of veterinary animals |
| KR102740384B1 (ko) | 2015-03-03 | 2024-12-06 | 키맵 리미티드 | 항체, 용도 및 방법 |
| GB2561352B (en) | 2017-04-10 | 2023-01-18 | Genome Res Ltd | Animal models and therapeutic molecules |
| KR20250026872A (ko) | 2018-03-16 | 2025-02-25 | 조에티스 서비시즈 엘엘씨 | 수의학적 용도를 위한 인터류킨-31 단클론성 항체 |
| GB2578867A (en) | 2018-10-09 | 2020-06-03 | Genome Res Ltd | Animal models and therapeutic molecules |
| GB202012331D0 (en) * | 2020-08-07 | 2020-09-23 | Petmedix Ltd | Therapeutic antibodies |
-
2023
- 2023-02-08 IL IL314314A patent/IL314314A/en unknown
- 2023-02-08 JP JP2024547510A patent/JP2025506488A/ja active Pending
- 2023-02-08 KR KR1020247029746A patent/KR20240139085A/ko active Pending
- 2023-02-08 US US18/837,256 patent/US20250340659A1/en active Pending
- 2023-02-08 EP EP23706072.8A patent/EP4476256A1/en active Pending
- 2023-02-08 AU AU2023219227A patent/AU2023219227A1/en active Pending
- 2023-02-08 MX MX2024009898A patent/MX2024009898A/es unknown
- 2023-02-08 CA CA3258958A patent/CA3258958A1/en active Pending
- 2023-02-08 WO PCT/GB2023/050281 patent/WO2023152486A1/en not_active Ceased
-
2024
- 2024-08-07 CL CL2024002361A patent/CL2024002361A1/es unknown
- 2024-08-12 CO CONC2024/0010901A patent/CO2024010901A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023540444A5 (enExample) | ||
| US20250122301A1 (en) | Cd25 antibodies | |
| JP2023179409A (ja) | 二重特異性抗体 | |
| RU2474588C2 (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
| JP7254699B2 (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| CN101903402B (zh) | 抗tl1a的人源化抗体 | |
| RU2014121043A (ru) | Биспецифические иммуносвязывающие средства, направленные против tnf и il-17 | |
| JP2021533726A5 (enExample) | ||
| JP2021515565A5 (enExample) | ||
| JP2021516974A5 (enExample) | ||
| JP2015502145A5 (enExample) | ||
| KR102167261B1 (ko) | 관절염 치료 | |
| CN116239698A (zh) | 双功能融合蛋白及其医药用途 | |
| JP2020511123A5 (enExample) | ||
| WO2009140348A4 (en) | Anti-il-6/il-6r antibodies and methods of use thereof | |
| CN104903352A (zh) | 多价结合蛋白组合物 | |
| JP2020007318A5 (enExample) | ||
| JP2023540444A (ja) | 治療用抗体 | |
| Sadeghalvad et al. | Introduction on monoclonal antibodies | |
| WO2022117079A1 (zh) | 结合胸腺基质淋巴细胞生成素的抗体及其应用 | |
| JP2011518857A (ja) | 治療用のｇｍ−ｃｓｆおよびｉｌ−１７阻害剤 | |
| JP2007501847A (ja) | 自己／同種免疫状態の治療用抗ＦｃＲｎ抗体 | |
| JP2016501877A5 (enExample) | ||
| CN118165106A (zh) | 抗犬il-31单克隆抗体及其应用 | |
| JP2023550628A5 (enExample) |